Back to Search Start Over

Design Considerations for Clinical Trials of Autonomic Modulation Therapies Targeting Hypertension and Heart Failure

Authors :
Kenneth M. Stein
Felix Mahfoud
Robert S. Kieval
Gaetano M. De Ferrari
Hermann Haller
Ileana L. Piña
Nadim Yared
Faiez Zannad
Sverre E. Kjeldsen
George L. Bakris
Michel Azizi
Wendy Gattis Stough
Centre d'investigation clinique plurithématique Pierre Drouin [Nancy] (CIC-P)
Centre d'investigation clinique [Nancy] (CIC)
Université de Lorraine (UL)-Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL)-Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)
Défaillance Cardiovasculaire Aiguë et Chronique (DCAC)
Université de Lorraine (UL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)
College of Pharmacy and Health Sciences [Campbell University]
Campbell University College
Universitätsklinikum des Saarlandes
Institute of Medical Engineering and Science [Cambridge] (IMES)
Massachusetts Institute of Technology (MIT)
ASH Comprehensive Hypertension Center [The University of Chicago Medicine]
The University of Chicago Medicine [Chicago]
Oslo University Hospital [Oslo]
Institute of Clinical Medicine [Oslo]
Faculty of Medicine [Oslo]
University of Oslo (UiO)-University of Oslo (UiO)
CVRx, Inc.
Medizinische Hochschule Hannover (MHH)
Fondazione IRCCS Policlinico San Matteo [Pavia]
Università di Pavia
Montefiore-Einstein Cancer Center
Boston Scientific
Hôpital Européen Georges Pompidou [APHP] (HEGP)
Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)
CIC AP-HP (hegp Ex-Broussais)/inserm
Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)
Université Paris Descartes - Paris 5 (UPD5)
Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL)-Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL)
Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL)
Università degli Studi di Pavia = University of Pavia (UNIPV)
Centre d'investigation clinique plurithématique Pierre Drouin (CIC-P)
Fondazione IRCCS Policlinico San Matteo
Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)
Source :
Hypertension, Hypertension, American Heart Association, 2014, 65 (1), pp.5-15. ⟨10.1161/HYPERTENSIONAHA.114.04057⟩, Hypertension, 2014, 65 (1), pp.5-15. ⟨10.1161/HYPERTENSIONAHA.114.04057⟩
Publication Year :
2014
Publisher :
HAL CCSD, 2014.

Abstract

Several device-based approaches to autonomic nervous system modulation are under investigation for the treatment of resistant hypertension and heart failure (Table 1).1 This line of research has evolved from the recognition that these diseases originate or are worsened by excess sympathetic activity and loss of parasympathetic tone.9–13 Drug therapies, including β-blockers, α-blockers, and centrally acting antihypertensive drugs, can modulate these neurohormonal systems, but they are often insufficient to control blood pressure (BP) or are limited by side effects or nonadherence. Technological innovations have produced devices that modulate the autonomic nervous system, including renal denervation, carotid baroreceptor stimulation, vagal nerve stimulation, and spinal cord stimulation. View this table: Table 1. Select Completed and Ongoing Clinical Trials of Autonomic Modulation Therapies in Hypertension and Heart Failure In Europe, several autonomic modulation therapy devices have received the Conformite Europeenne mark.14 US Food and Drug Administration evaluation of these devices is ongoing. The need for adequately powered, randomized, controlled studies with longer follow-up to capture definitive evidence of safety and effectiveness has been noted.14–17 The 9th and 10th Global Cardiovascular Clinical Trialists Forum (Paris, France, December 2012 and December 2013) convened a panel of primary investigators of ongoing trials, along with biostatisticians, National Institutes of Health scientists, European, and United States regulators, and medical device and pharmaceutical industry scientists to discuss the strengths and limitations of current clinical trials, optimal designs for future trials, approvability of new devices, and considerations for integrating these technologies into practice. This article summarizes the key discussion points and identifies knowledge gaps in this field that need to be addressed by additional research. The mechanisms of autonomic modulation are complex, and a comprehensive review of these mechanisms is outside the scope of this article. Briefly, all existing strategies aim to decrease central sympathetic outflow. Renal …

Details

Language :
English
ISSN :
0194911X and 15244563
Database :
OpenAIRE
Journal :
Hypertension, Hypertension, American Heart Association, 2014, 65 (1), pp.5-15. ⟨10.1161/HYPERTENSIONAHA.114.04057⟩, Hypertension, 2014, 65 (1), pp.5-15. ⟨10.1161/HYPERTENSIONAHA.114.04057⟩
Accession number :
edsair.doi.dedup.....1f0612de6f190463e461d902daf534da
Full Text :
https://doi.org/10.1161/HYPERTENSIONAHA.114.04057⟩